|
| Press Releases |
|
 |
|
| Tuesday, July 8, 2025 |
|
|
エーザイ、CDP から「サプライヤー・エンゲージメント評価」において最高評価である「サプライヤー・エンゲージメント・リーダー」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、国際的な環境非営利団体 CDP1より「サプライヤー・エンゲージメント評価」において、最高評価の「サプライヤー・エンゲージメント・リーダー」に選定されましたのでお知らせします。 more info >> |
|
| Monday, June 2, 2025 |
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
| Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
|
エーザイ、国内 OTC 医薬品初となるプロトンポンプ阻害薬「パリエット(R) S」新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、胃酸逆流などによるつらい胸やけ・胃痛に優れた効果を発揮する「パリエット®S（要指導医薬品）」を全国の薬局、ドラッグストアにて新発売します。 more info >> |
|
| Thursday, May 29, 2025 |
|
|
エーザイ、米国におけるレンバチニブに関する特許侵害訴訟の勝訴について |
| 当社は、当社創製の経口チロシンキナーゼ阻害剤「レンビマ®」（一般名：レンバチニブメシル酸塩）に関する特許（米国特許第 11,186,547 号、以下、ʼ547 特許）侵害を理由として、本剤に関する後発医薬品の簡略新薬承認申請（ANDA）を行った後発医薬品メーカー(Shilpa Medicare Limited（以下、Shilpa））に対し、2019 年 11 月に米国ニュージャージー州連邦地方裁判所に特許侵害訴訟を提起していましたが、2025 年 5 月 28 日に、当社勝訴の判決を得ましたので、お知らせします。 more info >> |
|
| Wednesday, May 28, 2025 |
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
| Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Wednesday, May 21, 2025 |
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2025 年 5 月 30 日から6 月３日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2025 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
| Friday, May 16, 2025 |
|
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
| Wednesday, April 30, 2025 |
|
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
| Friday, April 18, 2025 |
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Executive Agility & DealMaker Launch Strategic Collaboration to Power Digital Capital Raising for IPO Readiness
Feb 26, 2026 02:59 HKT/SGT
|
|
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 26, 2026 02:52: JST
|
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59: JST
|
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST
|
|
|
雲頂新耀股東特別大會通過商業化服務協議等決議案
Feb 25, 2026 20:59 HKT/SGT
|
|
|
云顶新耀股东特别大会通过商业化服务协议等决议案
Feb 25, 2026 20:59 HKT/SGT
|
|
|
Doubleview Gold Corp. Reports Updated Mineral Resource Estimate as of February 25, 2026 Including a Copper Equivalent Mineral Resource: 609 (Mt) of Measured and Indicated Resources at 0.43% CuEq containing CuEq 5.82 Billion lbs. 503 (Mt) of Inferred Resources at 0.41% CuEq containing CuEq 4.57 Billion lbs
Feb 25, 2026 20:59 HKT/SGT
|
|
|
Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST
|
|
|
DOCOMO and Keio University Demonstrate World's First Stable, High-Fidelity Robot Teleoperation via Commercial 5G Using Low-Latency Slicing
Feb 25, 2026 21:01 JST
|
|
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 25, 2026 19:57 HKT/SGT
|
|
|
DOCOMO Successfully Demonstrates AI Application Operation Using Virtualized Radio Access Network (vRAN) Infrastructure
Feb 25, 2026 20:50 JST
|
|
|
DOCOMO Begins Commercial Deployment of Agentic AI System for Network Maintenance Using One of the World's Largest Datasets
Feb 25, 2026 20:40 JST
|
|
|
Champion REIT Delivers Resilient Performance, Proactive Tenant Mix Optimisation Drives Sustainable Development
Feb 25, 2026 19:30 HKT/SGT
|
|
|
冠君產業信託於挑戰中彰顯韌性 積極優化租戶組合推動持續發展
Feb 25, 2026 19:30 HKT/SGT
|
|
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
